In a case-control study, leptin was measured by ELISA in two independent cohorts of biopsy-proven obese NAFLD patients and healthy-liver controls aimed to evaluate this biomarker as a non-invasive method for NAFLD diagnosis. This evidence concerns the gene LEP and metabolic dysfunction-associated steatotic liver disease.